HIV/Aids

11 February 2008

Early ARV treatment prolongs life

Research has shown that ARV therapy for HIV infection given to patients in their 30s earlier than is currently recommended could prolong survival by more than two years.

0
Initiating antiretroviral therapy for HIV infection earlier than is currently recommended by guidelines could prolong survival by more than two years among patients in their 30s, new research hints.

"Even after the harmful consequences of combination antiretroviral therapy were incorporated into our model, earlier treatment was still favoured for many scenarios that we evaluated," Dr R. Scott Braithwaite, at Yale University in West Haven, Connecticut, and colleagues report.

Specifically, their computer simulation model suggests that starting anti-HIV therapy once the number of CD4 cells drops to 500 cells per microlitre of blood - rather than at lower levels recommended by current guidelines - would be beneficial.

Doctors use CD4 cell counts to gauge the function of the immune system. As levels of these cells decline, so does the ability of the patient's immune system to function.

Earlier the better
For 30-year-olds, the researchers found that earlier initiation of combination antiretroviral therapy was "always preferred" regardless of the amount of virus circulating in the body because the risks (increase in death from drug toxicity, increase in accumulation of resistance mutations, and decrease in future drug options) were small compared with the benefit (decrease in HIV-related death from the effect of therapy on the natural history of HIV).

The computer simulation showed that 40-year-old patients would benefit from therapy started at a CD4 count of 500 when their viral load (the amount of HIV circulating in the body) exceeds 100 000 copies of the virus per millilitre of blood.

For 50-year-olds, the risk of toxic side effects of antiretroviral therapy outweighed the benefits of early treatment. "Our findings may affect clinical care because they provide evidence in favour of treatment in several settings in which clinical guidelines are ambiguous," Braithwaite and colleagues note, "increasing life expectancy by as much as 2.8 years." – (ReutersHealth) - (February 2008)

Read more:
ARV's and care saves lives
Fear over ARV resistance

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

HIV/Aids expert

Dr Sindisiwe van Zyl qualified at the University of Pretoria before working for an HIV/AIDS NPO in Soweto for many years. She was named one of the Mail & Guardian's Top 200 Young South Africans in 2012.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules